Aligned Genetics Q1 2026: Consolidated Revenue 3.64B KRW, Operating Profit 0.23B KRW, Down YoY

Consolidated revenue: 3.64B KRW, operating profit: 0.23B KRW, net income: 0.42B KRW (estimated decline YoY)
Separate revenue: 2.68B KRW, operating profit: 0.08B KRW, net income: 0.12B KRW (down 22%, 87%, 80% YoY respectively)
R&D expenditure ratio: 29.1% of revenue, maintaining high level
Debt-to-equity ratio: 57%; net debt-to-equity ratio: 29% (up from 16% at end of 2025)
Completed acquisition of headquarters building; GMP facility expansion in progress
Continued development of molecular diagnostics business (genescale)
Q1 2026 operating cash flow: 0.14B KRW (consolidated)
Treasury shares: 320,622 shares (acquired in 2025, no change in current quarter)